Difference between revisions of "Estrogen receptor"

From Libre Pathology
Jump to navigation Jump to search
Line 10: Line 10:
**[[Invasive ductal carcinoma of the breast]] - most.
**[[Invasive ductal carcinoma of the breast]] - most.
*[[Endometrial carcinoma]]s.
*[[Endometrial carcinoma]]s.
===Occasionally positive===
*[[Lung adenocarcinoma]] - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.<ref name=pmid27069542>{{Cite journal  | last1 = Tanaka | first1 = K. | last2 = Shimizu | first2 = K. | last3 = Kakegawa | first3 = S. | last4 = Ohtaki | first4 = Y. | last5 = Nagashima | first5 = T. | last6 = Kaira | first6 = K. | last7 = Horiguchi | first7 = J. | last8 = Oyama | first8 = T. | last9 = Takeyoshi | first9 = I. | title = Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. | journal = Am J Transl Res | volume = 8 | issue = 1 | pages = 81-97 | month =  | year = 2016 | doi =  | PMID = 27069542 }}</ref>


==Negative==
==Negative==

Revision as of 20:31, 23 June 2016

Estrogen receptor, abbreviated ER, is a common immunostain.

General

In the context of breast pathology it is a class II IHC test, as it is used for treatment decisions by itself.[1]

Positive

Occasionally positive

Negative

See also

References

  1. Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.
  2. Tanaka, K.; Shimizu, K.; Kakegawa, S.; Ohtaki, Y.; Nagashima, T.; Kaira, K.; Horiguchi, J.; Oyama, T. et al. (2016). "Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.". Am J Transl Res 8 (1): 81-97. PMID 27069542.